This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
mtaschetta-millane Wed, 07/31/2024 - 06:00 July 31, 2024 — A novel study co-authored by a heart failure cardiologist at University Hospitals Harrington Heart & Vascular Institute, demonstrates the effectiveness of a newly developed scoring system in identifying patients with Heart Failure with PreservedEjectionFraction (HFpEF).
Increasing severity of obesity is associated with multiple characteristics that may contribute to the development or worsening of heart failure (HF) with preservedejectionfraction (HFpEF). of patients had BMI ≥30 kg/m 2. Strain measurements in all four chambers were maintained as BMI increased. Overall, 60.9%
BMI, body mass index; CI, confidence interval; LVEF, left ventricular ejectionfraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide. The primary outcome was a composite of cardiovascular death or worsening heart failure. In addition, dapagliflozin was safe and well-tolerated, irrespective of COPD status.
The primary outcomes were exercise capacity, diastolic function, and quality of life at baseline evaluation. Patients studied were older (68 years old), white (90%), obese (average BMI 34 kg/m2) individuals with an average LVEF of 61%. Outcomes and multivariate linear regression results are shown in Table 2.
The H2FPEF score and probability were developed to assist in heart failure with preservedejectionfraction (HFpEF) diagnosis. Survival analysis was performed (Outcome: PAH related-hospitalization or death). Significant predictors of outcomes were identified using Cox logistic regression analysis.
The analysis sought to determine whether phenotypic features and treatment effects of semaglutide vary by sex in obesity-related heart failure ( HF ) with preservedejectionfraction (HFpEF). Our study sheds light on these differences and the consistent benefits of semaglutide for women and men.”
2, 3] This association is more pronounced for those with class I obesity, which is a body mass index (BMI) between 30-35 kg/m2. These individuals tend to have a better prognosis when compared to both individuals with normal weight (BMI of 18.5 to 25 kg/m2) and underweight (BMI less than 18.5
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content